Intervention not reported
Overall survival · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to lower overall survival (low certainty).
1 finding from 1 review
Intervention not reported
Toxic death · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Adverse effects · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to higher quality of life (low certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).
1 finding from 1 review
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival (OS) · People with advanced non‐small cell lung cancer
Gefitinib showed no clear difference in overall survival (OS) compared with chemotherapy (moderate certainty).
2 findings from 1 review
Neutropenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower neutropenia compared with chemotherapy (high certainty).
1 finding from 1 review
Febrile neutropenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower febrile neutropenia compared with chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
Gefitinib showed no clear difference in progression‐free survival (PFS) compared with chemotherapy (moderate certainty).
2 findings from 1 review
Rash · People with advanced non‐small cell lung cancer
Gefitinib leads to higher skin rash compared with chemotherapy (high certainty).
1 finding from 1 review
Constipation · People with advanced non‐small cell lung cancer
Gefitinib leads to lower constipation compared with chemotherapy (high certainty).
1 finding from 1 review
Fatigue · People with advanced non‐small cell lung cancer
Gefitinib probably leads to lower fatigue compared with chemotherapy (moderate certainty).
1 finding from 1 review
Asthenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower asthenia compared with chemotherapy (high certainty).
1 finding from 1 review